Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: A retrospective case series - 14/03/15
Abstract |
Background |
Some patients with chronic extensive alopecia areata (AA) may be refractory to topical immunotherapy. Combination therapy is recommended for such patients. Efficacy and safety of a combination therapy with diphenylcyclopropenone (DPCP) and anthralin in chronic extensive AA is unknown.
Objective |
We sought to determine whether the combination therapy of DPCP and anthralin is superior to DPCP alone in chronic extensive AA.
Methods |
We retrospectively analyzed the efficacy, side effects, and relapse rates of DPCP (alone or with anthralin) in chronic extensive AA.
Results |
A total of 47 patients (22 were treated only with DPCP, and 25 with DPCP and anthralin for at least 30 weeks) were evaluated. Complete hair regrowth was observed in 36.4% and 72% of the patients who received DPCP and combination therapy, respectively (P = .01). Hair regrowth duration was shorter with combination therapy (P = .01). Regrowth rates of the eyebrows, eyelashes, and beard in patients on combination therapy were higher than those in patients on DPCP (P = .01). Side effects such as folliculitis, hyperpigmentation, and staining of skin, hair, and clothes were more common in combination therapy group.
Limitations |
The retrospective design and small number of patients are limitations.
Conclusion |
Combination therapy with DPCP and anthralin is superior to DPCP alone in chronic extensive AA.
Le texte complet de cet article est disponible en PDF.Key words : adverse effects, alopecia areata, alopecia totalis, alopecia universalis, anthralin, cignolin, diphencyprone, diphenylcyclopropenone, dithranol, folliculitis
Abbreviations used : AA, AT, AU, DPCP
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
|
Reprints not available from the authors. |
Vol 72 - N° 4
P. 640-650 - avril 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?